Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of Teplizumab in slowing the development of type 1 diabetes; and when he plans to roll-out that drug on the NHS.

Teplizumab was licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) in August 2025, to delay the onset of Stage 3 type 1 diabetes in adult and paediatric patients 8 years of age and older with Stage 2 type 1 diabetes. Newly licensed medicines are appraised by the National Institute for Health and Care Excellence (NICE), which is the independent body responsible for developing evidence-based guidance for the National Health Service on new medicines which represent a clinically and cost-effective use of resources. NICE aims wherever possible to issue draft guidance on new medicines close to the time of licensing and the NHS in England is legally required to fund NICE-recommended medicines, normally within three months of the publication of final guidance.

NICE is currently evaluating teplizumab and has published draft guidance for consultation in which it was unable to recommend teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes. Final guidance is due to be published on 26 November 2025.